Literature DB >> 17298393

Remote control of tumour-targeted Salmonella enterica serovar Typhimurium by the use of L-arabinose as inducer of bacterial gene expression in vivo.

Holger Loessner1, Anne Endmann, Sara Leschner, Kathrin Westphal, Manfred Rohde, Tewfik Miloud, Günter Hämmerling, Klaus Neuhaus, Siegfried Weiss.   

Abstract

We have used Salmonella enterica serovar Typhimurium (S. typhimurium) which are able to colonize tumours besides spleen and liver. Bacteria were equipped with constructs encoding green fluorescent protein or luciferase as reporters under control of the promoter PBAD that is inducible with L-arabinose. Reporter genes could be induced in culture but also when the bacteria resided within the mouse macrophages J774A.1. More important, strong expression of reporters by the bacteria could be detected in mice after administration of L-arabinose. This was especially pronounced in bacteria colonizing tumours. Histology demonstrated that the bacteria had accumulated in and close to necrotic areas of tumours. Bacterial gene induction was observed in both regions. PBAD is tightly controlled also in vivo because gene E of bacteriophage PhiX174 could be introduced as inducible suicide gene. The possibility to deliberately induce genes in bacterial carriers within the host should render them extremely powerful tools for tumour therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17298393     DOI: 10.1111/j.1462-5822.2007.00890.x

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  41 in total

1.  Advances in bacterial cancer therapies using synthetic biology.

Authors:  Tiffany Chien; Anjali Doshi; Tal Danino
Journal:  Curr Opin Syst Biol       Date:  2017-05-23

Review 2.  Tumour-targeting bacteria engineered to fight cancer.

Authors:  Shibin Zhou; Claudia Gravekamp; David Bermudes; Ke Liu
Journal:  Nat Rev Cancer       Date:  2018-12       Impact factor: 60.716

3.  The N terminus of type III secretion needle protein YscF from Yersinia pestis functions to modulate innate immune responses.

Authors:  Patrick Osei-Owusu; Danielle L Jessen Condry; Melody Toosky; William Roughead; David S Bradley; Matthew L Nilles
Journal:  Infect Immun       Date:  2015-02-02       Impact factor: 3.441

Review 4.  Salmonella-allies in the fight against cancer.

Authors:  Sara Leschner; Siegfried Weiss
Journal:  J Mol Med (Berl)       Date:  2010-06-05       Impact factor: 4.599

5.  Modulating Pathogenesis with Mobile-CRISPRi.

Authors:  Jiuxin Qu; Neha K Prasad; Michelle A Yu; Shuyan Chen; Amy Lyden; Nadia Herrera; Melanie R Silvis; Emily Crawford; Mark R Looney; Jason M Peters; Oren S Rosenberg
Journal:  J Bacteriol       Date:  2019-10-21       Impact factor: 3.490

Review 6.  Potent and tumor specific: arming bacteria with therapeutic proteins.

Authors:  Nele Van Dessel; Charles A Swofford; Neil S Forbes
Journal:  Ther Deliv       Date:  2015-03

7.  IFNγ expression by an attenuated strain of Salmonella enterica serovar Typhimurium improves vaccine efficacy in susceptible TLR4-defective C3H/HeJ mice.

Authors:  Samia M Al-Ojali; C B Tara Moore; Maria J Fernandez-Cabezudo; Basel K Al-Ramadi
Journal:  Med Microbiol Immunol       Date:  2012-06-10       Impact factor: 3.402

8.  Targeted deletion of the ara operon of Salmonella typhimurium enhances L-arabinose accumulation and drives PBAD-promoted expression of anti-cancer toxins and imaging agents.

Authors:  Hyun Hong; Daejin Lim; Geun-Joong Kim; Seung-Hwan Park; Hyeon Sik Kim; Yeongjin Hong; Hyon E Choy; Jung-Joon Min
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

9.  Yersinia pestis with regulated delayed attenuation as a vaccine candidate to induce protective immunity against plague.

Authors:  Wei Sun; Kenneth L Roland; Xiaoying Kuang; Christine G Branger; Roy Curtiss
Journal:  Infect Immun       Date:  2010-01-19       Impact factor: 3.441

10.  The role of relA and spoT in Yersinia pestis KIM5 pathogenicity.

Authors:  Wei Sun; Kenneth L Roland; Christine G Branger; Xiaoying Kuang; Roy Curtiss
Journal:  PLoS One       Date:  2009-08-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.